• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study
Publication date: Available online 3 May 2018 Source:The Lancet HIV Author(s): Lene Ryom, Jens D Lundgren, Wafaa El-Sadr, Peter Reiss, Ole Kirk, Matthew Law, Andrew Phillips, Rainer Weber, Eric Fontas, Antonella d' Arminio Monforte, Stéphane De Wit, Francois Dabis, Camilla I Hatleberg, Caroline Sabin, Amanda Mocroft Background Although earlier protease inhibitors have been associated with increased risk of cardiovascular disease, whether this increased risk also applies to more contemporary protease inhibitors is unknown. We aimed to assess whether cumulative use of ritonavir-boosted atazanavir and ritonavir-boosted daru...
Source: The Lancet HIV - May 15, 2018 Category: Infectious Diseases Source Type: research

Darunavir Linked to Heightened Heart Disease Risk Darunavir Linked to Heightened Heart Disease Risk
The early protease inhibitors are known to increase risk for heart attack, stroke, and sudden cardiac death. Now, data from the D:A:D study raise concerns about next-generation drugs.Medscape Medical News
Source: Medscape Today Headlines - February 17, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Evaluation of Cardiovascular Disease Risk in HIV-1 –Infected Patients Treated with Darunavir
ConclusionsThis comprehensive review of Janssen-sponsored clinical trial, post-marketing, and epidemiological data does not suggest that CVD should be considered an important risk for users of darunavir.
Source: Drugs in R&D - July 10, 2018 Category: Drugs & Pharmacology Source Type: research

Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States
CONCLUSIONS: Over a short average follow-up period of <2 years, INSTI use among treatment-naïve PLWH was associated with an increased risk of several cardiometabolic outcomes, such as CHF, myocardial infarction and lipid disorders, compared to non-INSTI use. Further research accounting for additional potential confounders and with longer follow-up is warranted to more accurately and precisely quantify the impact of INSTI-containing ART on long-term cardiometabolic outcomes.PMID:37306118 | DOI:10.1002/jia2.26123
Source: Journal of the International AIDS Society - June 12, 2023 Category: Infectious Diseases Authors: Peter F Rebeiro Bruno Emond Carmine Rossi Brahim K Bookhart Aditi Shah Gabrielle Caron-Lapointe Marie-H élène Lafeuille Prina Donga Source Type: research